Contextual conditioning in rats as an animal model for generalized anxiety disorder

Cognitive, Affective and Behavioral Neuroscience

Volumn 11, Issue 2, 2011, Pages 228-244

  Luyten, Laura ^a   Vansteenwegen, Debora ^b   Van Kuyck, Kris ^a   Gabriëls, Loes ^c   Nuttin, Bart ^a,c  

^a KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Animal model; Construct validity; Contextual conditioning; Face validity; Generalized anxiety disorder; Predictive validity; Rat

Indexed keywords

ANIMAL; ANXIETY; ANXIETY DISORDER; ARTICLE; CONDITIONING; DISEASE MODEL; FEAR; HUMAN; PSYCHOLOGICAL ASPECT; RAT; VALIDATION STUDY;

ANIMALS; ANXIETY; ANXIETY DISORDERS; CONDITIONING (PSYCHOLOGY); DISEASE MODELS, ANIMAL; FEAR; HUMANS; RATS; VALIDATION STUDIES AS TOPIC;

EID: 80051645877     PISSN: 15307026     EISSN: None     Source Type: Journal    
DOI: 10.3758/s13415-011-0021-6     Document Type: Article

References (172)

1. Adams, J. B., Pyke, R. E., Costa, J., Cutler, N. R., Schweizer, E., Wilcox, C. S., et al. (1995). A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology, 15, 428-434. (Pubitemid 26005593)
2. Aliyev, N. A., & Aliyev, Z. N. (2008). Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, doubleblind placebo-controlled study. European Psychiatry, 23, 109-114. (Pubitemid 351284508)
3. Allgulander, C. (2006). Generalized anxiety disorder: what are we missing? European Neuropsychopharmacology, 16(Suppl. 2), S101-S108. (Pubitemid 43947550)
4. Alvarez, R. P., Biggs, A., Chen, G., Pine, D. S., & Grillon, C. (2008). Contextual fear conditioning in humans: cortical-hippocampal and amygdala contributions. The Journal of Neuroscience, 28, 6211-6219.
5. Ameli, R., Ip, C., & Grillon, C. (2001). Contextual fear-potentiated startle conditioning in humans: replication and extension. Psychophysiology, 38, 383-390. (Pubitemid 32422281)
6. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders: DSM-IV-TR (4th ed.). Washington, DC: American Psychiatric Association.
7. Anagnostaras, S. G., Gale, G. D., & Fanselow, M. S. (2001). Hippocampus and contextual fear conditioning: recent controversies and advances. Hippocampus, 11, 8-17.
8. Antoniadis, E. A., & McDonald, R. J. (1999). Discriminative fear conditioning to context expressed by multiple measures of fear in the rat. Behavioural Brain Research, 101, 1-13. (Pubitemid 29197205)
9. Barger, S. D., & Sydeman, S. J. (2005). Does generalized anxiety disorder predict coronary heart disease risk factors independently of major depressive disorder? Journal of Affective Disorders, 88, 87-91. (Pubitemid 41160418)
10. Bear, M. F., Connors, B. W., & Paradiso, M. A. (2001). Neuroscience: exploring the brain (2nd ed.). Baltimore, MD: Lippincott Williams & Wilkins.
11. Becker, E. S., Goodwin, R., Holting, C., Hoyer, J., & Margraf, J. (2003). Content of worry in the community: what do people with generalized anxiety disorder or other disorders worry about? Journal of Nervous Mental Disorders, 191, 688-691. (Pubitemid 37296183)
12. Behar, E., DiMarco, I. D., Hekler, E. B., Mohlman, J., & Staples, A. M. (2009). Current theoretical models of generalized anxiety disorder (GAD): conceptual review and treatment implications. Journal of Anxiety Disorders, 23, 1011-1023
13. Bjerrum, H., Allerup, P., Thunedborg, K., Jakobsen, K., & Bech, P. (1992). Treatment of generalized anxiety disorder: comparison of a new beta-blocking drug (CGP 361 A), low-dose neuroleptic (flupenthixol), and placebo. Pharmacopsychiatry, 25, 229-232.
14. Bourin, M. (1997). Animal models of anxiety: are they suitable for predicting drug action in humans? Polish Journal of Pharmacology, 49, 79-84. (Pubitemid 27304039)
15. Brawman-Mintzer, O., Lydiard, R. B., Bradwejn, J., Villarreal, G., Knapp, R., Emmanuel, N., et al. (1997). Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. The American Journal of Psychiatry, 154, 700-702. (Pubitemid 27197610)
16. Bredy, T. W., & Barad, M. (2008). The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and reconsolidation of conditioned fear. Learning & Memory, 15, 39-45. (Pubitemid 351171604)
17. Buhr, K., & Dugas, M. J. (2009). The role of fear of anxiety and intolerance of uncertainty in worry: an experimental manipulation. Behaviour Research and Therapy, 47, 215-223.
18. Bystritsky, A., Kerwin, L., Feusner, J. D., & Vapnik, T. (2008). A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder. Psychopharmacology Bulletin, 41, 46-51.
19. Candido, A., Gonzalez, F., & de Brugada, I. (2004). Safety signals from avoidance learning but not from yoked classical conditioning training pass both summation and retardation tests for inhibition. Behavioral Processes, 66, 153-160. (Pubitemid 38521266)
20. Cannistraro, P. A., & Rauch, S. L. (2003). Neural circuitry of anxiety: evidence from structural and functional neuroimaging studies. Psychopharmacology Bulletin, 37, 8-25.
21. Carrive, P. (2000). Conditioned fear to environmental context: Cardiovascular and behavioral components in the rat. Brain Research, 858, 440-445. (Pubitemid 30120009)
22. Chessick, C. A., Allen, M. H., Thase, M., Batista Miralha da Cunha, A. B., Kapczinski, F. F., de Lima, M. S., et al. (2006). Azapirones for generalized anxiety disorder. Cochrane Database of Systematic Reviews, CD006115.
23. Chou, K. L. (2009). Age at onset of generalized anxiety disorder in older adults. The American Journal of Geriatric Psychiatry, 17, 455-464.
24. Christoffersen, G. R., Christensen, L. H., Harrington, N. R., Macphail, E. M., & Riedel, G. (1999). Task-specific enhancement of shortterm, but not long-term, memory by class I metabotropic glutamate receptor antagonist 1-aminoindan-1, 5-dicarboxylic acid in rats. Behavioural Brain Research, 101, 215-226. (Pubitemid 29236365)
25. Chrousos, G. P. (2009). Stress and disorders of the stress system. Nature Reviews Endocrinology, 5, 374-381.
26. Cordero, M. I., Merino, J. J., & Sandi, C. (1998). Correlational relationship between shock intensity and corticosterone secretion on the establishment and subsequent expression of contextual fear conditioning. Behavioral Neuroscience, 112, 885-891. (Pubitemid 28397370)
27. Cutler, N. R., Sramek, J. J., Keppel Hesselink, J. M., Krol, A., Roeschen, J., Rickels, K., et al. (1993). A double-blind, placebocontrolled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial. Journal of Clinical Psychopharmacology, 13, 429-437. (Pubitemid 24026105)
28. Davis, M. (1986). Pharmacological and anatomical analysis of fear conditioning using the fear-potentiated startle paradigm. Behavioral Neuroscience, 100, 814-824. (Pubitemid 17002689)
29. Davis, M. (1998). Are different parts of the extended amygdale involved in fear versus anxiety? Biological Psychiatry, 44, 1239-1247. (Pubitemid 29015862)
30. Davis, M., Walker, D. L., & Lee, Y. (1997). Amygdala and bed nucleus of the stria terminalis: differential roles in fear and anxiety measured with the acoustic startle reflex. Philosophical Transactions of the Royal Society B, 352, 1675-1687. (Pubitemid 28000461)
31. Davis, M., Walker, D. L., Miles, L., & Grillon, C. (2010). Phasic vs. sustained fear in rats and humans: role of the extended amygdala in fear vs. anxiety. Neuropsychopharmacology, 35, 105-135.
32. De Bellis, M. D., Keshavan, M. S., Shifflett, H., Iyengar, S., Dahl, R. E., Axelson, D. A., et al. (2002). Superior temporal gyrus volumes in pediatric generalized anxiety disorder. Biological Psychiatry, 51, 553-562. (Pubitemid 34327330)
33. de Beurs, E., Beekman, A. T., van Balkom, A. J., Deeg, D. J., van Dyck, R., & van Tilburg, W. (1999). Consequences of anxiety in older persons: its effect on disability, well-being and use of health services. Psychological Medicine, 29, 583-593. (Pubitemid 29261346)
34. De Souza, E. B. (1995). Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology, 20, 789-819. (Pubitemid 26050396)
35. Deak, T., Nguyen, K. T., Ehrlich, A. L., Watkins, L. R., Spencer, R. L., Maier, S. F., et al. (1999). The impact of the nonpeptide corticotropin- releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology, 140, 79-86. (Pubitemid 29011144)
36. Dubovsky, S. L. (1990). Generalized anxiety disorder: new concepts and psychopharmacologic therapies. The Journal of Clinical Psychiatry, 51(Suppl), 3-10. (Pubitemid 20032419)
37. Dugas, M. J., Buhr, K., & Ladouceur, R. (2004). The role of intolerance of uncertainty. In R. G. Heimberg, C. L. Turk, & D. S. Mennin (Eds.), Generalized anxiety disorder: advances in research and practice. New York: Guilford Press. pp. 143-163.
38. Dugas, M. J., Gagnon, F., Ladouceur, R., & Freeston, M. H. (1998). Generalized anxiety disorder: a preliminary test of a conceptual model. Behaviour Research and Therapy, 36, 215-226. (Pubitemid 28234081)
39. Dunayevich, E., Erickson, J., Levine, L., Landbloom, R., Schoepp, D. D., & Tollefson, G. D. (2008). Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology, 33, 1603-1610. (Pubitemid 351684700)
40. Enkelmann, R. (1991). Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology, 105, 428-432.
41. Espejo, E. F. (1997). Effects of weekly or daily exposure to the elevated plus-maze in male mice. Behavioural Brain Research, 87, 233-238. (Pubitemid 27425379)
42. Fanselow, M. S. (1982). The postshock activity burst. Animal Learning & Behavior, 10, 448-454. (Pubitemid 13108333)
43. Fanselow, M. S. (2000). Contextual fear, gestalt memories, and the hippocampus. Behavioural Brain Research, 110, 73-81. (Pubitemid 30236293)
44. Fanselow, M. S., & Helmstetter, F. J. (1988). Conditional analgesia, defensive freezing, and benzodiazepines. Behavioral Neuroscience, 102, 233-243.
45. Fendt, M. (2001). Injections of the NMDA receptor antagonist aminophosphonopentanoic acid into the lateral nucleus of the amygdala block the expression of fear-potentiated startle and freezing. The Journal of Neuroscience, 21, 4111-4115. (Pubitemid 32466503)
46. Fendt, M., & Fanselow, M. S. (1999). The neuroanatomical and neurochemical basis of conditioned fear. Neuroscience and Biobehavioral Reviews, 23, 743-760. (Pubitemid 29282023)
47. File, S. E., Gonzalez, L. E., & Gallant, R. (1998). Role of the basolateral nucleus of the amygdala in the formation of a phobia. Neuropsychopharmacology, 19, 397-405. (Pubitemid 28451595)
48. File, S. E., Zangrossi, H., Jr., Viana, M., & Graeff, F. G. (1993). Trial 2 in the elevated plus-maze: a different form of fear? Psychopharmacology, 111, 491-494. (Pubitemid 23205675)
49. Fossey, M. D., Lydiard, R. B., Ballenger, J. C., Laraia, M. T., Bissette, G., & Nemeroff, C. B. (1996). Cerebrospinal fluid corticotropinreleasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biological Psychiatry, 39, 703-707. (Pubitemid 26157605)
50. Fricchione, G. (2004). Clinical practice. Generalized anxiety disorder. The New England Journal of Medicine, 351, 675-682.
51. Gambi, F., De Berardis, D., Campanella, D., Carano, A., Sepede, G., Salini, G., et al. (2005). Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. Journal of Psychopharmacology, 19, 483-487. (Pubitemid 41392302)
52. Gerra, G., Zaimovic, A., Zambelli, U., Timpano, M., Reali, N., Bernasconi, S., et al. (2000). Neuroendocrine responses to psychological stress in adolescents with anxiety disorder. Neuropsychobiology, 42, 82-92. (Pubitemid 30665980)
53. Gewirtz, J. C., Falls, W. A., & Davis, M. (1997). Normal conditioned inhibition and extinction of freezing and fear-potentiated startle following electrolytic lesions of medical prefrontal cortex in rats. Behavioral Neuroscience, 111, 712-726. (Pubitemid 27335383)
54. Gewirtz, J. C., McNish, K. A., & Davis, M. (1998). Lesions of the bed nucleus of the stria terminalis block sensitization of the acoustic startle reflex produced by repeated stress, but not fear-potentiated startle. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 22, 625-648. (Pubitemid 28281227)
55. Gewirtz, J. C., McNish, K. A., & Davis, M. (2000). Is the hippocampus necessary for contextual fear conditioning? Behavioural Brain Research, 110, 83-95. (Pubitemid 30236294)
56. Geyer, M. A., & Markou, A. (1995). Animal models of psychiatric disorders. In F. Bloom (Ed.), Psychopharmacology: the fourth generation of progress. New York: Raven.
57. Gleitman, L. R., & Landau, B. (1994). The acquisition of the lexicon. Cambridge: MIT Press.
58. Golbin, A. Z., Kravitz, H. M., & Keith, L. G. (2004). Sleep psychiatry. London: Parthenon.
59. Goodwin, R. D., Keyes, K. M., Stein, M. B., & Talley, N. J. (2009). Peptic ulcer and mental disorders among adults in the community: the role of nicotine and alcohol use disorders. Psychosomatic Medicine, 71, 463-468.
60. Goodwin, R. D., & Stein, M. B. (2002). Generalized anxiety disorder and peptic ulcer disease among adults in the United States. Psychosomatic Medicine, 64, 862-866. (Pubitemid 35417128)
61. Gorwood, P. (2004). Generalized anxiety disorder and major depressive disorder comorbidity: an example of genetic pleiotropy? European Psychiatry, 19, 27-33. (Pubitemid 38210426)
62. Gosselin, P., & Laberge, B. (2003). Etiological factors of generalized anxiety disorder. L'Encéphale, 29, 351-361. (Pubitemid 37203758)
63. Graeff, F. G., Netto, C. F., & Zangrossi, H., Jr. (1998). The elevated Tmaze as an experimental model of anxiety. Neuroscience and Biobehavioral Reviews, 23, 237-246. (Pubitemid 29011625)
64. Graeff, F. G., & Zangrossi, H., Jr. (2002). Animal models of anxiety disorders. In H. A. H. D'haenen, J. A. den Boer, & P. Willner (Eds.), Biological psychiatry (pp. 879-893). Chichester: Wiley.
65. Gray, T. S., Piechowski, R. A., Yracheta, J. M., Rittenhouse, P. A., Bethea, C. L., & Van de Kar, L. D. (1993). Ibotenic acid lesions in the bed nucleus of the stria terminalis attenuate conditioned stress-induced increases in prolactin, ACTH and corticosterone. Neuroendocrinology, 57, 517-524. (Pubitemid 23170158)
66. Griebel, G. (1995). 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacology & Therapeutics, 65, 319-395.
67. Grillon, C. (2002). Startle reactivity and anxiety disorders: aversive conditioning, context, and neurobiology. Biological Psychiatry, 52, 958-975. (Pubitemid 35356354)
68. Grillon, C., Baas, J. M., Cornwell, B., & Johnson, L. (2006). Context conditioning and behavioral avoidance in a virtual reality environment: effect of predictability. Biological Psychiatry, 60, 752-759. (Pubitemid 44427771)
69. Grillon, C., Baas, J. M., Pine, D. S., Lissek, S., Lawley, M., Ellis, V., et al. (2006). The benzodiazepine alprazolam dissociates contextual fear from cued fear in humans as assessed by fear-potentiated startle. Biological Psychiatry, 60, 760-766. (Pubitemid 44427760)
70. Grillon, C., Cordova, J., Levine, L. R., & Morgan, C. A. (2003). Anxiolytic effects of a novel group: II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology, 168, 446-454. (Pubitemid 36994028)
71. Grillon, C., Cordova, J., Morgan, C. A., Charney, D. S., & Davis, M. (2004). Effects of the beta-blocker propranolol on cued and contextual fear conditioning in humans. Psychopharmacology, 175, 342-352. (Pubitemid 39361922)
72. Grillon, C., Lissek, S., Rabin, S., McDowell, D., Dvir, S., & Pine, D. S. (2008). Increased anxiety during anticipation of unpredictable but not predictable aversive stimuli as a psychophysiologic marker of panic disorder. The American Journal of Psychiatry, 165, 898-904. (Pubitemid 351948722)
73. Grillon, C., Pine, D. S., Lissek, S., Rabin, S., Bonne, O., & Vythilingam, M. (2009). Increased anxiety during anticipation of unpredictable aversive stimuli in posttraumatic stress disorder but not in generalized anxiety disorder. Biological Psychiatry, 66, 47-53.
74. Gros, D. F., Antony, M. M., McCabe, R. E., & Swinson, R. P. (2009). Frequency and severity of the symptoms of irritable bowel syndrome across the anxiety disorders and depression. Journal of Anxiety Disorders, 23, 290-296.
75. Gue, M., Junien, J. L., & Bueno, L. (1991). Conditioned emotional response in rats enhances colonic motility through the central release of corticotropin-releasing factor. Gastroenterology, 100, 964-970.
76. Guile, M. N. (1987). Differential gastric ulceration in rats receiving shocks on either fixed-time or variable-time schedules. Behavioral Neuroscience, 101, 139-140. (Pubitemid 17028965)
77. Härter, M. C., Conway, K. P., & Merikangas, K. R. (2003). Associations between anxiety disorders and physical illness. European Archives of Psychiatry and Clinical Neuroscience, 253, 313-320. (Pubitemid 38075973)
78. Herman, J. P., & Cullinan, W. E. (1997). Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends in Neurosciences, 20, 78-84. (Pubitemid 27050702)
79. Hettema, J. M., Prescott, C. A., & Kendler, K. S. (2001). A population-based twin study of generalized anxiety disorder in men and women. Journal of Nervous Mental Disorders, 189, 413-420. (Pubitemid 32730203)
80. Hoehn-Saric, R., McLeod, D. R., Funderburk, F., & Kowalski, P. (2004). Somatic symptoms and physiologic responses in generalized anxiety disorder and panic disorder: an ambulatory monitor study. Archives of General Psychiatry, 61, 913-921. (Pubitemid 39181081)
81. Hoehn-Saric, R., McLeod, D. R., Lee, Y. B., & Zimmerli, W. D. (1991). Cortisol levels in generalized anxiety disorder. Psychiatry Research, 38, 313-315.
82. Holaway, R. M., Heimberg, R. G., & Coles, M. E. (2006). A comparison of intolerance of uncertainty in analogue obsessivecompulsive disorder and generalized anxiety disorder. Journal of Anxiety Disorders, 20, 158-174. (Pubitemid 43197800)
83. Hubbard, D. T., Nakashima, B. R., Lee, I., & Takahashi, L. K. (2007). Activation of basolateral amygdala corticotropin-releasing factor 1 receptors modulates the consolidation of contextual fear. Neuroscience, 150, 818-828. (Pubitemid 350235791)
84. Hunot, V., Churchill, R., Teixeira, V., & Silva de Lima, M. (2007). Psychological therapies for generalised anxiety disorder. Cochrane Database of Systematic Reviews, CD001848.
85. Inoue, T., Hashimoto, S., Tsuchiya, K., Izumi, T., Ohmori, T., & Koyama, T. (1996). Effect of citalopram, a selective serotonin reuptake inhibitor, on the acquisition of conditioned freezing. European Journal of Pharmacology, 311, 1-6. (Pubitemid 26298492)
86. Inoue, T., Tsuchiya, K., & Koyama, T. (1996). Serotonergic activation reduces defensive freezing in the conditioned fear paradigm. Pharmacology, Biochemistry and Behavior, 53, 825-831. (Pubitemid 26112948)
87. Izumi, T., Inoue, T., Tsuchiya, K., Hashimoto, S., Ohmori, T., & Koyama, T. (1996). Effect of the selective CCKB receptor antagonist LY288513 on conditioned fear stress in rats. European Journal of Pharmacology, 300, 25-31.
88. Jones, S. V., Heldt, S. A., Davis, M., & Ressler, K. J. (2005). Olfactory-mediated fear conditioning in mice: Simultaneous measurements of fear-potentiated startle and freezing. Behavioral Neuroscience, 119, 329-335. (Pubitemid 40279523)
89. Kapczinski, F., Lima, M. S., Souza, J. S., & Schmitt, R. (2003). Antidepressants for generalized anxiety disorder. Cochrane Database of Systematic Reviews, CD003592.
90. Kessler, R. C., DuPont, R. L., Berglund, P., & Wittchen, H. U. (1999). Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. The American Journal of Psychiatry, 156, 1915-1923.
91. Kim, M., & Davis, M. (1993). Electrolytic lesions of the amygdale block acquisition and expression of fear-potentiated startle even with extensive training but do not prevent reacquisition. Behavioral Neuroscience, 107, 580-595. (Pubitemid 23259624)
92. Kitaichi, Y., Inoue, T., Nakagawa, S., Izumi, T., & Koyama, T. (2006). Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats. European Journal of Pharmacology, 532, 236-245.
93. Lang, P. J., Bradley, M. M., & Cuthbert, B. N. (1998). Emotion, motivation, and anxiety: brain mechanisms and Psychophysiology. Biological Psychiatry, 44, 1248-1263. (Pubitemid 29015863)
94. Lang, P. J., Davis, M., & Ohman, A. (2000). Fear and anxiety: animal models and human cognitive Psychophysiology. Journal of Affective Disorders, 61, 137-159. (Pubitemid 32119263)
95. Lee, S., Wu, J., Ma, Y. L., Tsang, A., Guo, W. J., & Sung, J. (2009). Irritable bowel syndrome is strongly associated with generalized anxiety disorder: a community study. Alimentary Pharmacology & Therapeutics, 30, 643-651.
96. Li, X. B., Inoue, T., Hashimoto, S., & Koyama, T. (2001). Effect of chronic administration of flesinoxan and fluvoxamine on freezing behavior induced by conditioned fear. European Journal of Pharmacology, 425, 43-50. (Pubitemid 32728298)
97. Llorca, P. M., Spadone, C., Sol, O., Danniau, A., Bougerol, T., Corruble, E., et al. (2002). Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month doubleblind study. The Journal of Clinical Psychiatry, 63, 1020-1027. (Pubitemid 35388062)
98. Luyten, L., Casteels, C., Vansteenwegen, D., van Kuyck, K., Koole, M., Van Laere, K., et al. (2011). Bed nucleus of the stria terminalis hypermetabolism during expression of anxiety but not fear. Manuscript submitted for publication.
99. Luyten, L., Vansteenwegen, D., van Kuyck, K., Deckers, D., & Nuttin, B. (2011). Optimization of a contextual conditioning protocol for rats using combined measurements of startle amplitude and freezing: The effects of shock intensity and different types of conditioning. Journal of Neuroscience Methods, 194, 305-311.
100. Luyten, L., Vansteenwegen, D., van Kuyck, K., & Nuttin, B. (2011). Optimization of a hronic contextual conditioning protocol in rats: The effect of different numbers of explicitly unpaired toneshock presentations on freezing time and startle amplitude. Manuscript submitted for publication.
101. Lyonfields, J. D., Borkovec, T. D., & Thayer, J. F. (1995). Vagal tone in generalized anxiety disorder and the effects of aversive imagery and worrisome thinking. Behavior Therapy, 26, 457-466.
102. Mackintosh, M. A., Gatz, M., Wetherell, J. L., & Pedersen, N. L. (2006). A twin study of lifetime generalized anxiety disorder (GAD) in older adults: genetic and environmental influences shared by neuroticism and GAD. Twin Research and Human Genetics, 9, 30-37. (Pubitemid 43384790)
103. Maier, S. F., & Seligman, M. E. P. (1976). Learned helplessness- theory and evidence. Journal of Experimental Psychology: General, 105, 3-46.
104. Maki, Y., Inoue, T., Izumi, T., Muraki, I., Ito, K., Kitaichi, Y., et al. (2000). Monoamine oxidase inhibitors reduce conditioned fear stress-induced freezing behavior in rats. European Journal of Pharmacology, 406, 411-418.
105. Mantella, R. C., Butters, M. A., Amico, J. A., Mazumdar, S., Rollman, B. L., Begley, A. E., et al. (2008). Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinology, 33, 773-781.
106. Marschner, A., Kalisch, R., Vervliet, B., Vansteenwegen, D., & Buchel, C. (2008). Dissociable roles for the hippocampus and the amygdala in human cued versus context fear conditioning. The Journal of Neuroscience, 28, 9030-9036.
107. Mathew, S. J., Mao, X., Coplan, J. D., Smith, E. L., Sackeim, H. A., Gorman, J. M., et al. (2004). Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study. The American Journal of Psychiatry, 161, 1119-1121. (Pubitemid 38736002)
108. Mathew, S. J., Price, R. B., Mao, X., Smith, E. L., Coplan, J. D., Charney, D. S., et al. (2008). Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biological Psychiatry, 63, 891-898. (Pubitemid 351458451)
109. McLeod, D. R., Hoehn-Saric, R., Porges, S. W., Kowalski, P. A., & Clark, C. M. (2000). Therapeutic effects of imipramine are counteracted by its metabolite, desipramine, in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology, 20, 615-621.
110. McNish, K. A., Gewirtz, J. C., & Davis, M. (1997). Evidence of contextual fear after lesions of the hippocampus: a disruption of freezing but not fear-potentiated startle. The Journal of Neuroscience, 17, 9353-9360. (Pubitemid 27498461)
111. Menard, J., & Treit, D. (1999). Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neuroscience and Biobehavioral Reviews, 23, 591-613. (Pubitemid 29086927)
112. Mendels, J., Krajewski, T. F., Huffer, V., Taylor, R. J., Secunda, S., Schless, A., et al. (1986). Effective short-term treatment of generalized anxiety disorder with trifluoperazine. The Journal of Clinical Psychiatry, 47, 170-174. (Pubitemid 16109750)
113. Michelson, D., Levine, L. R., Dellva, M. A., Mesters, P., Schoepp, D. D., Dunayevich, E., et al. (2005). Clinical studies with mGlu2/3 agonists: LY354740 compared with placebo in patients with generalized anxiety disorder. Neuropharmacology, 49(Suppl. 1), 1-279.
114. Milanov, I. (2007). Clinical and electromyographic characteristics of tremor in patients with generalized anxiety disorder. Electromyography and Clinical Neurophysiology, 47, 3-9. (Pubitemid 46380453)
115. Mineka, S., & Hendersen, R. W. (1985). Controllability and predictability in acquired motivation. Annual Review of Psychology, 36, 495-529.
116. Mineka, S., & Kihlstrom, J. F. (1978). Unpredictable and uncontrollable events: a new perspective on experimental neurosis. Journal of Abnormal Psychology, 87, 256-271. (Pubitemid 8314237)
117. Mineka, S., & Zinbarg, R. (2006). A contemporary learning theory perspective on the etiology of anxiety disorders: It's not what you thought it was. The American Psychologist, 61, 10-26. (Pubitemid 43134219)
118. Mula, M., Pini, S., & Cassano, G. B. (2007). The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. Journal of Clinical Psychopharmacology, 27, 263-272. (Pubitemid 46763308)
119. Narrow, W. E., Rae, D. S., Robins, L. N., & Regier, D. A. (2002). Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Archives of General Psychiatry, 59, 115-123. (Pubitemid 34137378)
120. Nishikawa, H., Inoue, T., Masui, T., Izumi, T., & Koyama, T. (2007). Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31, 926-931. (Pubitemid 46660305)
121. Nishitsuji, K., To, H., Murakami, Y., Kodama, K., Kobayashi, D., Yamada, T., et al. (2004). Tandospirone in the treatment of generalised anxiety disorder and mixed anxiety-depression: results of a comparatively high dosage trial. Clinical Drug Investigation, 24, 121-126. (Pubitemid 38316601)
122. Noel, F., Stevens, G., & Bradford, D. (1996). Flesinoxan treatment of generalized anxiety disorder: a fixed dose, placebo-controlled trial [Abstract]. European Neuropsychopharmacology, 6(Suppl. 4), 144.
123. Nutt, D., & Malizia, A. (2006). Anxiety and OCD-the chicken or the egg? Journal of Psychopharmacology, 20, 729-731.
124. Ohmura, Y., Yamaguchi, T., Izumi, T., Matsumoto, M., & Yoshioka, M. (2008). Corticotropin releasing factor in the median raphe nucleus is involved in the retrieval of fear memory in rats. European Journal of Pharmacology, 584, 357-360.
125. Orman, R., & Stewart, M. (2007). Hemispheric differences in protein kinase C betaII levels in the rat amygdala: baseline asymmetry and lateralized changes associated with cue and context in a classical fear conditioning paradigm. Neuroscience, 144, 797-807. (Pubitemid 46013984)
126. Paulesu, E., Sambugaro, E., Torti, T., Danelli, L., Ferri, F., Scialfa, G., et al. (2010). Neural correlates of worry in generalized anxiety disorder and in normal controls: a functional MRI study. Psychological Medicine, 40, 117-124.
127. Pezze, M. A., Bast, T., & Feldon, J. (2003). Significance of dopamine transmission in the rat medial prefrontal cortex for conditioned fear. Cerebral Cortex, 13, 371-380. (Pubitemid 36373683)
128. Pfeffer, C. R., Altemus, M., Heo, M., & Jiang, H. (2007). Salivary cortisol and psychopathology in children bereaved by the September 11, 2001 terror attacks. Biological Psychiatry, 61, 957-965. (Pubitemid 46482462)
129. Phillips, R. G., & LeDoux, J. E. (1994). Lesions of the dorsal hippocampal formation interfere with background but not foreground contextual fear conditioning. Learning & Memory, 1, 34-44. (Pubitemid 2113957)
130. Pitts, M. W., Todorovic, C., Blank, T., & Takahashi, L. K. (2009). The central nucleus of the amygdala and corticotropin-releasing factor: insights into contextual fear memory. The Journal of Neuroscience, 29, 7379-7388.
131. Pollack, M. H. (2009). Refractory generalized anxiety disorder. The Journal of Clinical Psychiatry, 70(Suppl. 2), 32-38.
132. Pollack, M. H., Simon, N. M., Zalta, A. K., Worthington, J. J., Hoge, E. A., Mick, E., et al. (2006). Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biological Psychiatry, 59, 211-215. (Pubitemid 43208966)
133. Pomara, N., Willoughby, L. M., Sidtis, J. J., Cooper, T. B., & Greenblatt, D. J. (2005). Cortisol response to diazepam: Its relationship to age, dose, duration of treatment, and presence of generalized anxiety disorder. Psychopharmacology, 178, 1-8. (Pubitemid 40298685)
134. Portugal, G. S., & Gould, T. J. (2007). Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning. Pharmacology, Biochemistry and Behavior, 88, 179-187. (Pubitemid 350116002)
135. Ray, W. J., Molnar, C., Aikins, D., Yamasaki, A., Newman, M. G., Castonguay, L., et al. (2009). Startle response in generalized anxiety disorder. Depression and Anxiety, 26, 147-154.
136. Rescorla, R. A. (1969). Conditioned inhibition of fear. In N. J. Mackintosh & W. K. Honig (Eds.), Fundamental issues in associative learning. Halifax: Dalhousie University Press. pp. 65-89
137. Resstel, L. B., Alves, F. H., Reis, D. G., Crestani, C. C., Correa, F. M., & Guimaraes, F. S. (2008). Anxiolytic-like effects induced by acute reversible inactivation of the bed nucleus of stria terminalis. Neuroscience, 154, 869-876.
138. Resstel, L. B., Joca, S. R., Moreira, F. A., Correa, F. M., & Guimaraes, F. S. (2006). Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behavioural Brain Research, 172, 294-298. (Pubitemid 44148829)
139. Rickels, K., DeMartinis, N., & Aufdembrinke, B. (2000). A doubleblind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology, 20, 12-18. (Pubitemid 30056348)
140. Rickels, K., Downing, R., Schweizer, E., & Hassman, H. (1993). Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Archives of General Psychiatry, 50, 884-895. (Pubitemid 23330980)
141. Riedel, G., Harrington, N. R., Kozikowski, A. P., Sandager-Nielsen, K., & Macphail, E. M. (2002). Variation of CS salience reveals group II mGluR-dependent and -independent forms of conditioning in the rat. Neuropharmacology, 43, 205-214. (Pubitemid 35247608)
142. Risbrough, V. B., & Stein, M. B. (2006). Role of corticotrophin releasing factor in anxiety disorders: a translational research perspective. Hormones and Behavior, 50, 550-561. (Pubitemid 44307112)
143. Roemer, L., Molina, S., Litz, B. T., & Borkovec, T. D. (1996). Preliminary investigation of the role of previous exposure to potentially traumatizing events in generalized anxiety disorder. Depression and Anxiety, 4, 134-138. (Pubitemid 27237376)
144. Ron, M. A., & Robbins, T. W. (Eds.). (2003). Disorders of brain and mind 2. Cambridge: Cambridge University Press.
145. Rynn,M., Russell, J., Erickson, J., Detke, M. J., Ball, S., Dinkel, J., et al. (2008). Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depression and Anxiety, 25, 182-189. (Pubitemid 351499896)
146. Santos, J. M., Gargaro, A. C., Oliveira, A. R., Masson, S., & Brandao, M. L. (2005). Pharmacological dissociation of moderate and high contextual fear as assessed by freezing behavior and fearpotentiated startle. European Neuropsychopharmacology, 15, 239-246. (Pubitemid 40193433)
147. Santos, J. M., Martinez, R. C., & Brandao, M. L. (2006). Effects of acute and subchronic treatments with fluoxetine and desipramine on the memory of fear in moderate and high-intensity contextual conditioning. European Journal of Pharmacology, 542, 121-128. (Pubitemid 44066375)
148. Seligman, M. E. (1968). Chronic fear produced by unpredictable electric shock. Journal of Comparative and Physiological Psychology, 66, 402-411.
149. Shekhar, A., Truitt, W., Rainnie, D., & Sajdyk, T. (2005). Role of stress, corticotrophin releasing factor (CRF) and amygdale plasticity in chronic anxiety. Stress, 8, 209-219. (Pubitemid 43163254)
150. Simon, N. M., Zalta, A. K., Worthington, J. J., 3rd, Hoge, E. A., Christian, K. M., Stevens, J. C., et al. (2006). Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. Depression and Anxiety, 23, 373-376. (Pubitemid 44619789)
151. Snyderman, S. H., Rynn, M. A., & Rickels, K. (2005). Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. Journal of Clinical Psychopharmacology, 25, 497-499. (Pubitemid 41368377)
152. Sramek, J. J., Zarotsky, V., & Cutler, N. R. (2002). Generalised anxiety disorder: treatment options. Drugs, 62, 1635-1648. (Pubitemid 34848371)
153. Stein, M. B. (2009). Neurobiology of generalized anxiety disorder. The Journal of Clinical Psychiatry, 70(Suppl. 2), 15-19.
154. Sullivan, G. M., Apergis, J., Bush, D. E., Johnson, L. R., Hou, M., & Ledoux, J. E. (2004). Lesions in the bed nucleus of the stria terminalis disrupt corticosterone and freezing responses elicited by a contextual but not by a specific cue-conditioned fear stimulus. Neuroscience, 128, 7-14. (Pubitemid 39140675)
155. Tadic, A., Rujescu, D., Szegedi, A., Giegling, I., Singer, P.,Möller, H.-J., et al. (2003). Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression. American Journal of Medical Genetics Part B, 117B, 1-6 (Pubitemid 37059352)
156. Takahashi, T.,Morinobu, S., Iwamoto, Y.,& Yamawaki, S. (2006). Effect of paroxetine on enhanced contextual fear induced by single prolonged stress in rats. Psychopharmacology, 189, 165-173. (Pubitemid 44691539)
157. Thayer, J. F., Friedman, B. H., & Borkovec, T. D. (1996). Autonomic characteristics of generalized anxiety disorder and worry. Biological Psychiatry, 39, 255-266. (Pubitemid 26083149)
158. Tiba, P. A., Oliveira, M. G., Rossi, V. C., Tufik, S., & Suchecki, D. (2008). Glucocorticoids are not responsible for paradoxical sleep deprivation-induced memory impairments. Sleep, 31, 505-515. (Pubitemid 351694273)
159. Turk, C. L., Heimberg, R. G., Luterek, J. A., Mennin, D. S., & Fresco, D. M. (2005). Emotion dysregulation in generalized anxiety disorder: a comparison with social anxiety disorder. Cognitive Therapy and Research, 29, 89-106. (Pubitemid 40386172)
160. Tyrer, P. (1999). Anxiety: a multidisciplinary review. London: Imperial College Press.
161. Tyrer, P., & Baldwin, D. (2006). Generalised anxiety disorder. Lancet, 368, 2156-2166. (Pubitemid 44894560)
162. Ulrich-Lai, Y. M., & Herman, J. P. (2009). Neural regulation of endocrine and autonomic stress responses. Nature Reviews. Neuroscience, 10, 397-409.
163. Varia, I., & Rauscher, F. (2002). Treatment of generalized anxiety disorder with citalopram. International Clinical Psychopharmacology, 17, 103-107. (Pubitemid 34442190)
164. Verleye, M., & Gillardin, J. M. (2004). Effects of etifoxine on stressinduced hyperthermia, freezing behavior and colonic motor activation in rats. Physiology & Behavior, 82, 891-897. (Pubitemid 39297086)
165. Walker, D. L., Toufexis, D. J., & Davis, M. (2003). Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. European Journal of Pharmacology, 463, 199-216. (Pubitemid 36205081)
166. Willner, P. (1986). Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 10, 677-690. (Pubitemid 17185919)
167. Willner, P. (1997). Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology, 134, 319-329. (Pubitemid 28023396)
168. Willner, P., & Mitchell, P. J. (2002). The validity of animal models of predisposition to depression. Behavioural Pharmacology, 13, 169-188. (Pubitemid 34816463)
169. Wittchen, H. U., Carter, R. M., Pfister, H., Montgomery, S. A., & Kessler, R. C. (2000). Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. International Clinical Psychopharmacology, 15, 319-328.
170. Woody, S., & Rachman, S. (1994). Generalized anxiety disorder (GAD) as an unsuccessful search for safety. Clinical Psychology Review, 14, 743-753.
171. Wu, J. C., Buchsbaum, M. S., Hershey, T. G., Hazlett, E., Sicotte, N., & Johnson, J. C. (1991). PET in generalized anxiety disorder. Biological Psychiatry, 29, 1181-1199.
172. Zanoveli, J. M., Ferreira-Netto, C., & Brandao, M. L. (2007). Conditioned place aversion organized in the dorsal periaqueductal gray recruits the laterodorsal nucleus of the thalamus and the basolateral amygdala. Experimental Neurology, 208, 127-136. (Pubitemid 47600155)